187 related articles for article (PubMed ID: 18690873)
1. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
2. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
3. Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.
Diel IJ; Kurth AH; Sittig HB; Meden H; Maasberg M; Sandermann A; Bergner R
Support Care Cancer; 2010 Oct; 18(10):1305-12. PubMed ID: 20151162
[TBL] [Abstract][Full Text] [Related]
4. Ibandronate: efficacy in the treatment of metastatic bone disease.
Diel IJ
Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
[TBL] [Abstract][Full Text] [Related]
5. Ibandronate in metastatic bone disease: a review of preclinical data.
Bauss F; Body JJ
Anticancer Drugs; 2005 Feb; 16(2):107-18. PubMed ID: 15655407
[TBL] [Abstract][Full Text] [Related]
6. Ibandronate in profile: drug characteristics and clinical efficacy.
Reginster JY; Neuprez A; Bruyère O
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):941-51. PubMed ID: 18624681
[TBL] [Abstract][Full Text] [Related]
7. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
8. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials.
Geng CJ; Liang Q; Zhong JH; Zhu M; Meng FY; Wu N; Liang R; Yuan BY
BMJ Open; 2015 Jun; 5(6):e007258. PubMed ID: 26038356
[TBL] [Abstract][Full Text] [Related]
9. Ibandronate in metastatic bone pain.
Heidenreich A; Ohlmann C; Body JJ
Semin Oncol; 2004 Oct; 31(5 Suppl 10):67-72. PubMed ID: 15490379
[TBL] [Abstract][Full Text] [Related]
10. Renal safety of ibandronate.
Jackson GH
Oncologist; 2005; 10 Suppl 1():14-8. PubMed ID: 16264108
[TBL] [Abstract][Full Text] [Related]
11. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Epstein S
Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
[TBL] [Abstract][Full Text] [Related]
12. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.
Tripathy D; Body JJ; Bergström B
Clin Ther; 2004 Dec; 26(12):1947-59. PubMed ID: 15823760
[TBL] [Abstract][Full Text] [Related]
13. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
14. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
17. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
Pecherstorfer M
Expert Opin Pharmacother; 2008 Dec; 9(17):3111-9. PubMed ID: 19006482
[TBL] [Abstract][Full Text] [Related]
18. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.
Ringe JD; Body JJ
Clin Exp Rheumatol; 2007; 25(5):766-74. PubMed ID: 18078631
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.
Sittig HB
Onkologie; 2012; 35(6):380-7. PubMed ID: 22722461
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ibandronate in metastatic bone disease: review of clinical data.
Bell R
Oncologist; 2005; 10 Suppl 1():8-13. PubMed ID: 16264107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
